Cell Genesys to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif. -- Cell Genesys, Inc. (Nasdaq:CEGE CEGE Combat Equipment Group Europe CEGE comité des étudiants en génie électrique ) today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update on Monday, May 19, 2008 at 12:10 pm CEST/ 6:10 am EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT at the Rodman & Renshaw 5th Annual Global Healthcare Conference being held in Monte Carlo, Monaco. A live audio webcast of the presentation will be accessible through the Investor Relations Investor relations The process by which the corporation communicates with its investors. section of the Cell Genesys website, www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website. Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms--GVAX[R] cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. , which is being developed in partnership with Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (武田薬品工業株式会社 Limited, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at www.cellgenesys.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion